Dennis Hall


Canada Research Chair in Boron Chemistry for Catalysis and Drug Discovery

Tier 1 - 2017-11-01
Renewed: 2022-10-01
University of Alberta
Natural Sciences and Engineering Research Council

780-492-3141
dennis.hall@ualberta.ca

Research involves


Studying organic compounds that contain carbon-boron bonds to discover catalysts and chemical reactions that may change the way synthetic pharmaceutical drugs are produced.

Research relevance


This research will lead to “greener,” more cost-effective chemical reactions as well as opportunities for new health treatments, such as chemotherapeutic drugs.

Research summary


Nucleophilic functional groups—such as alcohols, amines and carboxylic acids—have electron-rich atoms that can donate electron pairs to form new covalent bonds. As Canada Research Chair in Boron Chemistry for Catalysis and Drug Discovery, Dr. Dennis Hall is studying both the catalytic activation of these groups and the scarcity of compound classes in drug discovery.

By exploiting the unique properties of hemiboronic heterocycles as exchangeable boron compounds, Hall and his research team are designing catalysts that can enable transformations in drug chemistry. He and his team are also evaluating the use of these catalysts in the development of chemotypes for drugs that can treat infective diseases. Ultimately, they aim to design both catalysts that are suitable for global commercialization and bioactive compounds that can be developed into drug candidates.